08:09 AM EST, 12/09/2024 (MT Newswires) -- Astrazeneca ( AZN ) said Sunday that results of a phase 3 trial of Calquence in combination with venetoclax demonstrated "statistically significant" improvement in progression-free survival in previously untreated adult patients with chronic lymphocytic leukemia, compared with standard-of-care chemoimmunotherapy.

Trial results showed that the combination therapy reduced the risk of disease progression or death by 35%, compared with standard-of-care, at a median follow up of 41 months, the drugmaker said. The combination therapy plus obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death, Astrazeneca ( AZN ) added.

Both investigational arms showed durable responses, with a 36-month progression-free survival rate for about 77% of patients under the calquence-venetoclax combination and about 83% of the patients with the addition of obinutuzumab, according to the statement.

Data on interim overall survival also showed a favorable trend, though assessment of overall survival continues as a secondary endpoint, Astrazeneca ( AZN ) said.

Shares were edging 0.3% higher in recent premarket activity.